Cytotoxic and antitumor activities of doxorubicin conjugates with the epidermal growth factor and its receptor-binding fragment

Journal of Drug Targeting

Volumn 10, Issue 7, 2002, Pages 567-571

  Lutsenko, S V ^a   Feldman, N B ^a   Severin, S E ^a  

^a Moscow Research Institute of Medical Ecology   (Russian Federation)

Author keywords

Conjugate; Doxorubicin; Drug resistance; Drug targeting; EGF; Receptor binding fragment

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA FETOPROTEIN; ANTHRACYCLINE ANTIBIOTIC AGENT; CARUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTARALDEHYDE; PEPTIDE; TRANSFERRIN; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SENSITIVITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FEMALE; FIBROBLASTS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0036875515     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1061186021000038058     Document Type: Article

References (28)

1. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model", Science 279, 377-380.
2. Cohen, S. and Carpenter, G. (1975) "Human epidermal growth factor: isolation and chemical and biological properties", Proc. Natl Acad. Sci. USA 72, 1317-1321.
3. Denekamp, J. (1993) "Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy", Br. J. Radiol. 66, 181-196.
4. Ennis, B.W., Lippman, M.E. and Dickson, R.B. (1991) "The EGF receptor system as a target for antitumor therapy", Cancer Investig. 9, 553-562.
5. Fitzpatrick, S.L., La Chance, M.P. and Schultz, G.S. (1984) "Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture", Cancer Res. 44, 3442-3447.
6. Hatano, T., Ohkawa, K. and Matsuda, M. (1993) "Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukaemia cell line, K562, in vitro", Tumor Biol. 14, 288-294.
7. Hurwitz, E., Levy, R., Mavon, R., Wilchek, M., Amon, R. and Sela, M. (1975) "The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities", Cancer Res. 35, 1175-1181.
8. Khazain, K., Schirrmacher, V. and Lichtner, R.B. (1993) "EGF receptor in neoplasia and metastasis", Cancer Metastasis Rev. 12, 255-274.
9. Komoriya, A., Hortsch, M., Meyers, C., Smith, M., Kanety, H. and Schlessinger, J. (1984) "Biologically active synthetic fragment of epidermal growth factor: localization of a major receptor-binding region", Proc. Natl Acad. Sci. USA 81, 1351-1355.
10. Lemieux, P. and Page, M. (1993) Σensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate", Anticancer Res. 13, 397-404.
11. Lowry, O.H., Rosenbrough, N.J., Farr, A.L. and Randall, R.J. (1951) "Protein measurement with Folin phenol reagent", J. Biol. Chem. 193, 265-275.
12. Lutsenko, S.V., Feldman, N.B., Gumanov, S.G., Rodina, A.V. and Severin, S.E. (2000a) "Cytotoxic activity, accumulation, and intracellular distribution of anthracycline antibiotics and their conjugates with the epidermal growth factor in sensitive and resistant MCF-7 cells", Biochemistry (Moscow) 65, 1299-1304.
13. Lutsenko, S.V., Feldman, N.B., Finakova, G.V., Gukasova, N.V., Petukhov, S.P., Posypanova, G.A., Skryabin, K.G. and Severin, S.E. (2000b) "Antitumor activity of alpha fetoprotein and epidermal growth factor conjugates in vitro and in vivo", Tumor Biol. 21, 367-374.
14. Maciag,T. (1990) "Molecular and cellular mechanisms of angiogenesis", Important Adv. Oncol., 85-98.
15. Marglin, A. and Merrifield, R.B. (1970) "Chemical synthesis of peptides and proteins", Annu. Rev. Biochem. 39, 841-866.
16. Modjtahedi, H. and Dean, Ch. (1994) "The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer", Int. J. Oncol. 4, 277-296.
17. Mosmann, T. (1983) "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxity assays", J. Immunol. Methods 65, 55-63.
18. Munns, J., Yaxley, J., Coomer, J., Lavin, M.F., Gardiner, R.A. and Watters, D. (1998) "Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of bladder cancer", Br. J. Urol. 82, 284-289.
19. Myers, C.E. and Chabner, B.A. (1990) "Anthracyclines", In: Chabner, B.A. and Collins, J.M., eds, Cancer Chemotherapy: Principles and Practice (J.B. Lippincott Company, Philadelphia), pp. 356-381.
20. O'Bryan, R., Baker, L., Gottlieb, J., Rivkin, S., Baicerzak, S., Grumet, G., Salmon, S., Moon, T. and Hoogstraten, B. (1977) "Dose response evaluation of adriamycin in human neoplasia", Cancer 39, 1940-1948.
21. Savage, C.R. and Cohen, S. (1972) "Epidermal growth factor and a new derivative: rapid isolation procedures and biological and chemical characterization", J. Biol. Chem. 247, 7609-7611.
22. Schally, A.V. and Nagy, A. (1999) "Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors", Eur. J. Endocrinol. 141, 1-14.
23. Schreiber, A.B., Winkler, M.E. and Derynck, R. (1986) "Transforming growth factor-α: a more potent angiogenic mediator then epidermal growth factor", Science 232, 1250-1253.
24. Severin, S.E., Moskaleva, E.Yu., Posypanova, G.A., Koromyslova, I.A., Shmyrev, I.I., Krivonos, A.V., Myagkikh, I.V., Feldman, N.B., Finakova, G.V., Luzhkov, Yu.M., Nakachian, R., Andreani, J. and Severin, E.S. (1996) "In vivo antitumor activity of cytotoxic drugs conjugated with human α-fetoprotein", Tumor Target. 2, 299-306.
25. Shaw, J.P., Akiyoshi, D.E., Arriyo, D.A., Rhoad, A.E., Sullivan, B., Thomas, J., Genbauffe, F.S., Bacha, P. and Nichols, J.C. (1991) "Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins", J. Biol. Chem. 266, 21118-21124.
26. Stavrovskaya, A.A. (2000) "Cellular mechanisms of multidrug resistance of tumor cells", Biochemistry (Moscow) 65(1), 95-106.
27. Trail, P.A., Willner, D. and Lasch, S.J. (1993) "Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates", Science 261, 212-215.
28. Tyle, P. and Ram, B.P. (1990) "Monoclonal antibodies, immunoconjugates end liposomes as targeted therapeutic systems", Target. Diagn. Ther. Ser. 3, 3-22.